Table 2.
Baseline characteristics of the included patients.
| No recurrence (N = 554) | Local AFX recurrence (N = 36) | Progression to PDS (N = 8) | Total (N = 598) | |
|---|---|---|---|---|
| Age, years | ||||
| Median | 76.0 | 81.0 | 80.0 | 76.7 |
| IQR | 68.9, 83.0 | 77.5, 85.5 | 78.0, 83.0 | 69.0, 83.1 |
| Sex | ||||
| Female | 112 (95.7%) | 3 (2.6%) | 2 (1.7%) | 117 (22.0%) |
| Male | 387 (90.6%) | 27 (6.3%) | 2 (0.5%) | 416 (78.0%) |
| Location | ||||
| Head and neck | 462 (90.1%) | 32 (6.2%) | 8 (1.6%) | 502 (93.8%) |
| Upper limbs | 15 (100.0%) | 0 (0.0%) | 0 (0.0%) | 15 (2.8%) |
| Truncus | 5 (100.0%) | 0 (0.0%) | 0 (0.0%) | 5 (0.9%) |
| Lower limbs | 13 (100.0%) | 0 (0.0%) | 0 (0.0%) | 13 (2.4%) |
| Previous skin cancer | ||||
| No | 132 (91.7%) | 9 (6.2%) | 3 (2.1%) | 144 (52.6%) |
| Yes | 116 (89.2%) | 9 (6.9%) | 5 (3.8%) | 130 (47.4%) |
| Surgery | ||||
| MMS | 136 (92.5%) | 7 (4.8%) | 4 (2.7%) | 147 (24.9%) |
| WLE | 410 (90.3%) | 29 (6.4%) | 4 (0.9%) | 443 (75.1%) |
| Size, mm | ||||
| Median | 13.0 | 12.8 | 4.9 | 12.8 |
| IQR | 9.0, 19.9 | 10.0, 20.0 | 4.9, 4.9 | 9.0, 20.0 |
| Margin, mm | ||||
| Median | 3.0 | 3.0 | 0.0 | 3.0 |
| IQR | 1.0, 5.0 | 1.5, 5.0 | 0.0, 0.0 | 1.0, 5.0 |
| <5 mm | 96 (86.5%) | 13 (11.7%) | 1 (0.9%) | 111 (64.9%) |
| 5–10 mm | 34 (87.2%) | 5 (12.8%) | 0 (0.0%) | 39 (22.8%) |
| >10 mm | 20 (95.2%) | 1 (4.8%) | 0 (0.0%) | 21 (12.3%) |
Note: Percentages in the three subgroups (no recurrence, local AFX recurrence, and progression to PDS). are compared to the total.
Abbreviations: AFX, atypical fibroxanthoma; IQR, interquartile range; MMS, Mohs' micrographic surgery; PDS, pleomorphic dermal sarcoma; WLE, wide local excision.